Editorial: an argument for low‐dose thiopurine allopurinol combination use as first‐line therapy in inflammatory bowel disease—authors’ reply
Linked Content This article is linked to Friedman et al and Ansari and Aziz papers. To view these articles visit https://doi.org/10.1111/apt.14571 and https://doi.org/10.1111/apt.14687.
Gespeichert in:
| Veröffentlicht in: | Alimentary pharmacology & therapeutics 2018-07, Vol.48 (1), p.98-99 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 99 |
|---|---|
| container_issue | 1 |
| container_start_page | 98 |
| container_title | Alimentary pharmacology & therapeutics |
| container_volume | 48 |
| creator | Friedman, A. B. Sparrow, M. P. |
| description | Linked Content
This article is linked to Friedman et al and Ansari and Aziz papers. To view these articles visit https://doi.org/10.1111/apt.14571 and https://doi.org/10.1111/apt.14687. |
| doi_str_mv | 10.1111/apt.14798 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2052808910</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2052808910</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3488-9ac7667cdfc984ef83940bbdd33b527ffa01ac7ae267ac40ad9d67449a3c63543</originalsourceid><addsrcrecordid>eNp1kc1u1DAURi0EokNhwQsgS2xgkdY_GcdhV1UtVKpEF2Ud3dgO48qJg-1olN08AgtY9PXmSfCQlgVSLVv24vj4Xn8IvaXkhOZxCmM6oWVVy2doRblYF4xw8RytCBN1wSTlR-hVjHeEEFER9hIdsVrKvMoV-n2hbfLBgvuEYcAQvk-9GRLufMDOb_e7n9pHg9PG-nEKdjAYnFuO3mHl-9YOkKwf8JQxiLizIaZ8zR3YtDEBxhnbIc_OQd9DfmzGrd8ah7WNBqLZ737BlDY-xP3uHgczuvk1etGBi-bNw36Mvl1e3J5_Ka6_fr46P7suFC-lLGpQlRCV0p3KzZhO8rokbas15-2aVV0HhGYEDBMVqJKArrWoyrIGrgRfl_wYfVi8Y_A_JhNT09uojHMwGD_FhpE1k0TWlGT0_X_onZ_CkKs7UFTU-c8Pwo8LpYKPMZiuGYPtIcwNJc0hqyZn1fzNKrPvHoxT2xv9j3wMJwOnC7C1zsxPm5qzm9tF-Qcxk6Vv</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2051692034</pqid></control><display><type>article</type><title>Editorial: an argument for low‐dose thiopurine allopurinol combination use as first‐line therapy in inflammatory bowel disease—authors’ reply</title><source>Wiley-Blackwell Journals</source><source>MEDLINE</source><source>Wiley Online Library Journals</source><source>EZB Electronic Journals Library</source><creator>Friedman, A. B. ; Sparrow, M. P.</creator><creatorcontrib>Friedman, A. B. ; Sparrow, M. P.</creatorcontrib><description>Linked Content
This article is linked to Friedman et al and Ansari and Aziz papers. To view these articles visit https://doi.org/10.1111/apt.14571 and https://doi.org/10.1111/apt.14687.</description><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1111/apt.14798</identifier><identifier>PMID: 29882984</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Allopurinol ; Azathioprine ; Humans ; Immunosuppressive Agents ; Inflammatory Bowel Diseases ; Intestine ; Mercaptopurine</subject><ispartof>Alimentary pharmacology & therapeutics, 2018-07, Vol.48 (1), p.98-99</ispartof><rights>2018 John Wiley & Sons Ltd</rights><rights>Copyright © 2018 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3488-9ac7667cdfc984ef83940bbdd33b527ffa01ac7ae267ac40ad9d67449a3c63543</cites><orcidid>0000-0003-2527-8044 ; 0000-0002-8106-1280</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fapt.14798$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fapt.14798$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29882984$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Friedman, A. B.</creatorcontrib><creatorcontrib>Sparrow, M. P.</creatorcontrib><title>Editorial: an argument for low‐dose thiopurine allopurinol combination use as first‐line therapy in inflammatory bowel disease—authors’ reply</title><title>Alimentary pharmacology & therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>Linked Content
This article is linked to Friedman et al and Ansari and Aziz papers. To view these articles visit https://doi.org/10.1111/apt.14571 and https://doi.org/10.1111/apt.14687.</description><subject>Allopurinol</subject><subject>Azathioprine</subject><subject>Humans</subject><subject>Immunosuppressive Agents</subject><subject>Inflammatory Bowel Diseases</subject><subject>Intestine</subject><subject>Mercaptopurine</subject><issn>0269-2813</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc1u1DAURi0EokNhwQsgS2xgkdY_GcdhV1UtVKpEF2Ud3dgO48qJg-1olN08AgtY9PXmSfCQlgVSLVv24vj4Xn8IvaXkhOZxCmM6oWVVy2doRblYF4xw8RytCBN1wSTlR-hVjHeEEFER9hIdsVrKvMoV-n2hbfLBgvuEYcAQvk-9GRLufMDOb_e7n9pHg9PG-nEKdjAYnFuO3mHl-9YOkKwf8JQxiLizIaZ8zR3YtDEBxhnbIc_OQd9DfmzGrd8ah7WNBqLZ737BlDY-xP3uHgczuvk1etGBi-bNw36Mvl1e3J5_Ka6_fr46P7suFC-lLGpQlRCV0p3KzZhO8rokbas15-2aVV0HhGYEDBMVqJKArrWoyrIGrgRfl_wYfVi8Y_A_JhNT09uojHMwGD_FhpE1k0TWlGT0_X_onZ_CkKs7UFTU-c8Pwo8LpYKPMZiuGYPtIcwNJc0hqyZn1fzNKrPvHoxT2xv9j3wMJwOnC7C1zsxPm5qzm9tF-Qcxk6Vv</recordid><startdate>201807</startdate><enddate>201807</enddate><creator>Friedman, A. B.</creator><creator>Sparrow, M. P.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>M7N</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-2527-8044</orcidid><orcidid>https://orcid.org/0000-0002-8106-1280</orcidid></search><sort><creationdate>201807</creationdate><title>Editorial: an argument for low‐dose thiopurine allopurinol combination use as first‐line therapy in inflammatory bowel disease—authors’ reply</title><author>Friedman, A. B. ; Sparrow, M. P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3488-9ac7667cdfc984ef83940bbdd33b527ffa01ac7ae267ac40ad9d67449a3c63543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Allopurinol</topic><topic>Azathioprine</topic><topic>Humans</topic><topic>Immunosuppressive Agents</topic><topic>Inflammatory Bowel Diseases</topic><topic>Intestine</topic><topic>Mercaptopurine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Friedman, A. B.</creatorcontrib><creatorcontrib>Sparrow, M. P.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><jtitle>Alimentary pharmacology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Friedman, A. B.</au><au>Sparrow, M. P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Editorial: an argument for low‐dose thiopurine allopurinol combination use as first‐line therapy in inflammatory bowel disease—authors’ reply</atitle><jtitle>Alimentary pharmacology & therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>2018-07</date><risdate>2018</risdate><volume>48</volume><issue>1</issue><spage>98</spage><epage>99</epage><pages>98-99</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><abstract>Linked Content
This article is linked to Friedman et al and Ansari and Aziz papers. To view these articles visit https://doi.org/10.1111/apt.14571 and https://doi.org/10.1111/apt.14687.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>29882984</pmid><doi>10.1111/apt.14798</doi><tpages>2</tpages><orcidid>https://orcid.org/0000-0003-2527-8044</orcidid><orcidid>https://orcid.org/0000-0002-8106-1280</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-2813 |
| ispartof | Alimentary pharmacology & therapeutics, 2018-07, Vol.48 (1), p.98-99 |
| issn | 0269-2813 1365-2036 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2052808910 |
| source | Wiley-Blackwell Journals; MEDLINE; Wiley Online Library Journals; EZB Electronic Journals Library |
| subjects | Allopurinol Azathioprine Humans Immunosuppressive Agents Inflammatory Bowel Diseases Intestine Mercaptopurine |
| title | Editorial: an argument for low‐dose thiopurine allopurinol combination use as first‐line therapy in inflammatory bowel disease—authors’ reply |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T15%3A16%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Editorial:%20an%20argument%20for%20low%E2%80%90dose%20thiopurine%20allopurinol%20combination%20use%20as%20first%E2%80%90line%20therapy%20in%20inflammatory%20bowel%20disease%E2%80%94authors%E2%80%99%20reply&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=Friedman,%20A.%20B.&rft.date=2018-07&rft.volume=48&rft.issue=1&rft.spage=98&rft.epage=99&rft.pages=98-99&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1111/apt.14798&rft_dat=%3Cproquest_cross%3E2052808910%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2051692034&rft_id=info:pmid/29882984&rfr_iscdi=true |